

Yasuo Hamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5141928/publications.pdf>

Version: 2024-02-01

62
papers

4,013
citations

471509

17
h-index

138484

58
g-index

64
all docs

64
docs citations

64
times ranked

4567
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
2	WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	1.6	2
3	A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 280-280.	1.6	1
4	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
5	Three-Year Follow-Up and Responseâ€“Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	7.0	27
6	Management of elderly patients with esophageal squamous cell cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 816-824.	1.3	4
7	Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2129-2134.	2.3	24
8	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 199-204.	1.3	2
9	Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). <i>Esophagus</i> , 2021, 18, 90-99.	1.9	30
10	FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)â€”The short-term results of cohort A and B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 202-202.	1.6	13
11	Prospective evaluation and refinement of an Sâ€“ dosage formula based on renal function for clinical application. <i>Cancer Science</i> , 2021, 112, 751-759.	3.9	5
12	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 204-204.	1.6	8
13	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 543.	2.6	3
14	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
15	Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). <i>Esophagus</i> , 2021, 18, 835-843.	1.9	15
16	A phase II study of chemoselection with docetaxel, cisplatin, and 5â€“fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4027-4027.	1.6	12
17	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. <i>Future Oncology</i> , 2021, 17, 2593-2603.	2.4	14
18	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. <i>Scientific Reports</i> , 2021, 11, 20003.	3.3	23
20	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
21	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposureâ€”Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). <i>Clinical Colorectal Cancer</i> , 2020, 19, 13-21.e3.	2.3	17
22	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
23	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. <i>Cell</i> , 2020, 183, 1420-1435.e21.	28.9	111
24	Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapyâ€”the P-SELECT trial (WJOG10617G)â€”a randomised phase II trial by the West Japan Oncology Group. <i>BMC Cancer</i> , 2020, 20, 548.	2.6	7
25	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	1.9	37
26	Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <i>Cancer Science</i> , 2020, 111, 1676-1684.	3.9	21
27	Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites. <i>Gastric Cancer</i> , 2020, 23, 363-372.	5.3	7
28	Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 60-67.	2.2	12
29	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	10.7	767
30	Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 27.	1.9	3
31	Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review. <i>BMC Nephrology</i> , 2019, 20, 120.	1.8	5
32	Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2019, 38, 65-69.	2.1	17
33	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
34	Treatment selection for esophageal cancer: evaluation from a nationwide database. <i>Esophagus</i> , 2018, 15, 109-114.	1.9	8
35	Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. <i>Investigational New Drugs</i> , 2018, 36, 939-948.	2.6	5
36	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. <i>Gastric Cancer</i> , 2018, 21, 429-438.	5.3	26

#	ARTICLE	IF	CITATIONS
37	Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, S2086-S2088.	1.4	0
38	Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 113-117.	1.0	0
39	Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 172-177.	1.6	8
40	Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand/Foot Syndrome. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 307.	1.6	4
41	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <i>Future Oncology</i> , 2018, 14, 3187-3198.	2.4	9
42	Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. <i>Oncology Letters</i> , 2018, 16, 1348-1356.	1.8	9
43	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 595-602.	2.3	12
44	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 631-639.	10.7	324
45	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
46	Curative resectability of gastrointestinal cancer identified from iron deficiency anemia. <i>Oncology Letters</i> , 2017, 14, 4301-4304.	1.8	1
47	Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. <i>Oncology Letters</i> , 2017, 14, 3697-3700.	1.8	1
48	Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. <i>Esophagus</i> , 2017, 14, 324-332.	1.9	9
49	Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1328-1334.	6.4	108
50	Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report. <i>Oncology Letters</i> , 2016, 11, 2408-2410.	1.8	8
51	Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). <i>Oncology Letters</i> , 2016, 11, 4049-4054.	1.8	7
52	Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. <i>Gastric Cancer</i> , 2016, 19, 876-886.	5.3	10
53	Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 389-392.	1.3	4
54	Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. <i>Oncology Letters</i> , 2016, 11, 231-233.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.. Journal of Clinical Oncology, 2016, 34, TPS175-TPS175.	1.6	19
56	Meta-analysis of postprogression survival for first-line gemcitabine monotherapy in patients with advanced pancreatic cancer: Positive relationship between subsequent anti-cancer therapy and overall survival.. Journal of Clinical Oncology, 2016, 34, e15687-e15687.	1.6	0
57	Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.. Journal of Clinical Oncology, 2016, 34, 4021-4021.	1.6	0
58	Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Molecular and Clinical Oncology, 2015, 3, 539-542.	1.0	17
59	Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. Japanese Journal of Clinical Oncology, 2015, 46, hv183.	1.3	11
60	A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). Oncologist, 2014, 19, 1131-1132.	3.7	15
61	Case series of preoperative triplet-regimen (docetaxel, CDDP and 5-fluorouracil) for borderline resectable T4 thoracic esophageal carcinoma. Esophagus, 2013, 10, 205-210.	1.9	3
62	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2011, 67, 1265-1272.	2.3	102